{"id":62204,"date":"2025-11-14T07:03:42","date_gmt":"2025-11-14T06:03:42","guid":{"rendered":"https:\/\/pharma-trend.com\/en\/galderma-completes-successful-placement-of-chf-175-million-bond\/"},"modified":"2025-11-14T07:03:42","modified_gmt":"2025-11-14T06:03:42","slug":"galderma-completes-successful-placement-of-chf-175-million-bond","status":"publish","type":"post","link":"https:\/\/pharma-trend.com\/en\/galderma-completes-successful-placement-of-chf-175-million-bond\/","title":{"rendered":"Galderma Completes Successful Placement of CHF 175 Million Bond"},"content":{"rendered":"
\n

ZUG, Switzerland–(BUSINESS WIRE)–NOT FOR DISTRIBUTION IN THE UNITED STATES OR IN ANY OTHER JURISDICTION IN WHICH SUCH DISTRIBUTION WOULD BE RESTRICTED BY APPLICABLE LAW OR REGULATION.<\/i><\/p>\n

<\/a>
<\/a><\/p>\n

\nGalderma Group AG (SIX:GALD), the pure-play dermatology category leader, today announced the successful placement of a single-tranche CHF 175 million Swiss franc-denominated bond. The bond has a maturity of 5 years and carries a fixed-rate annual coupon of 0.9425%.<\/p>\n

\nNet proceeds from the transaction will be used to partially refinance Galderma\u2019s existing bank term loan issued at its initial public offering (IPO) in March 2024, as well as for general corporate purposes. This marks the company\u2019s third CHF-bond issuance since listing.<\/p>\n

\nThe new bond will be listed on the SIX Swiss Exchange, with the settlement date expected on December 10, 2025. BNP Paribas and UBS jointly led the transaction.<\/p>\n

\nGalderma is rated BBB (stable outlook) by Fitch. The same rating is also expected to be assigned to the new bond.<\/p>\n

\nThe successful issuance is leverage-neutral and does not materially affect Galderma\u2019s full-year 2025 guidance on net financial expenses, as last communicated in the company\u2019s first half 2025 results on July 24, 2025.<\/p>\n

\nAbout Galderma<\/b><\/p>\n

\nGalderma (SIX: GALD) is the pure-play dermatology category leader, present in approximately 90 countries. We deliver an innovative, science-based portfolio of premium flagship brands and services that span the full spectrum of the fast-growing dermatology market through Injectable Aesthetics, Dermatological Skincare and Therapeutic Dermatology. Since our foundation in 1981, we have dedicated our focus and passion to the human body\u2019s largest organ \u2013 the skin \u2013 meeting individual consumer and patient needs with superior outcomes in partnership with healthcare professionals. Because we understand that the skin we are in shapes our lives, we are advancing dermatology for every skin story. For more information: www.galderma.com<\/a>.<\/p>\n

\nForward-looking statements<\/b><\/p>\n

\nCertain statements in this announcement are forward-looking statements. Forward-looking statements are statements that are not historical facts and may be identified by words such as “plans”, “targets”, “aims”, ” believes”, “expects”, “anticipates”, “intends”, “estimates”, “will”, “may”, “continues”, “should” and similar expressions. These forward-looking statements reflect, at the time, Galderma’s beliefs, intentions and current targets\/ aims concerning, among other things, Galderma’s results of operations, financial condition, industry, liquidity, prospects, growth and strategies and are subject to change. The estimated financial information is based on management’s current expectations and is subject to change. By their nature, forward-looking statements involve a number of risks, uncertainties and assumptions that could cause actual results or events to differ materially from those expressed or implied by the forward-looking statements. These risks, uncertainties and assumptions could adversely affect the outcome and financial consequences of the plans and events described herein. Actual results may differ from those set forth in the forward-looking statements as a result of various factors (including, but not limited to, future global economic conditions, changed market conditions, intense competition in the markets in which Galderma operates, costs of compliance with applicable laws, regulations and standards, diverse political, legal, economic and other conditions affecting Galderma\u2019s markets, and other factors beyond the control of Galderma). Neither Galderma nor any of their respective shareholders (as applicable), directors, officers, employees, advisors, or any other person is under any obligation to update or revise any forward-looking statements, whether as a result of new information, future events or otherwise. You should not place undue reliance on forward-looking statements, which speak of the date of this announcement. Statements contained in this announcement regarding past trends or events should not be taken as a representation that such trends or events will continue in the future. Some of the information presented herein is based on statements by third parties, and no representation or warranty, express or implied, is made as to, and no reliance should be placed on, the fairness, reasonableness, accuracy, completeness or correctness of this information or any other information or opinions contained herein, for any purpose whatsoever. Except as required by applicable law, Galderma has no intention or obligation to update, keep updated or revise this announcement or any parts thereof.<\/p>\n

Contacts<\/b> <\/p>\n

\nFor further information:<\/p>\n

<\/b>Media<\/i><\/b>
Christian Marcoux, M.Sc.
\n
Chief Communications Officer
\n
christian.marcoux@galderma.com<\/a>
+41 76 315 26 50<\/p>\n

Richard Harbinson
\n
Corporate Communications Director
\n
richard.harbinson@galderma.com<\/a>
+41 76 210 60 62<\/p>\n

Investors<\/i><\/b>
Emil Ivanov
\n
Head of Strategy, Investor Relations and ESG
\n
emil.ivanov@galderma.com<\/a>
+41 21 642 78 12<\/p>\n

Jessica Cohen
\n
Investor Relations and Strategy Director
\n
jessica.cohen@galderma.com<\/a>
+41 21 642 76 43<\/p>\n<\/div>\n","protected":false},"excerpt":{"rendered":"

ZUG, Switzerland–(BUSINESS WIRE)–NOT FOR DISTRIBUTION IN THE UNITED STATES OR IN ANY OTHER JURISDICTION IN WHICH SUCH DISTRIBUTION WOULD BE RESTRICTED BY APPLICABLE LAW OR REGULATION. Galderma Group AG (SIX:GALD), the pure-play dermatology category leader, today announced the successful placement of a single-tranche CHF 175 million Swiss franc-denominated bond. The bond has a maturity of … [Read more…]<\/a><\/span><\/p>\n","protected":false},"author":4,"featured_media":0,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[13],"tags":[],"class_list":{"0":"entry","1":"post","2":"publish","3":"author-business","4":"post-62204","6":"format-standard","7":"category-industry"},"yoast_head":"\nGalderma Completes Successful Placement of CHF 175 Million Bond - Pharma Trend<\/title>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/pharma-trend.com\/en\/galderma-completes-successful-placement-of-chf-175-million-bond\/\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"Galderma Completes Successful Placement of CHF 175 Million Bond - Pharma Trend\" \/>\n<meta property=\"og:description\" content=\"ZUG, Switzerland–(BUSINESS WIRE)–NOT FOR DISTRIBUTION IN THE UNITED STATES OR IN ANY OTHER JURISDICTION IN WHICH SUCH DISTRIBUTION WOULD BE RESTRICTED BY APPLICABLE LAW OR REGULATION. Galderma Group AG (SIX:GALD), the pure-play dermatology category leader, today announced the successful placement of a single-tranche CHF 175 million Swiss franc-denominated bond. The bond has a maturity of ... [Read more...]\" \/>\n<meta property=\"og:url\" content=\"https:\/\/pharma-trend.com\/en\/galderma-completes-successful-placement-of-chf-175-million-bond\/\" \/>\n<meta property=\"og:site_name\" content=\"Pharma Trend\" \/>\n<meta property=\"article:published_time\" content=\"2025-11-14T06:03:42+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/mms.businesswire.com\/media\/20251113705213\/en\/2643381\/22\/GALDERMA_LOGO_BLACK_RGB.jpg\" \/>\n<meta name=\"author\" content=\"Business Wire\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"Business Wire\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"4 minutes\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\\\/\\\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/galderma-completes-successful-placement-of-chf-175-million-bond\\\/#article\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/galderma-completes-successful-placement-of-chf-175-million-bond\\\/\"},\"author\":{\"name\":\"Business Wire\",\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/#\\\/schema\\\/person\\\/02d41342c7a74fa7f0032bb35ef0bb24\"},\"headline\":\"Galderma Completes Successful Placement of CHF 175 Million Bond\",\"datePublished\":\"2025-11-14T06:03:42+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/galderma-completes-successful-placement-of-chf-175-million-bond\\\/\"},\"wordCount\":724,\"publisher\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/#organization\"},\"image\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/galderma-completes-successful-placement-of-chf-175-million-bond\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/mms.businesswire.com\\\/media\\\/20251113705213\\\/en\\\/2643381\\\/22\\\/GALDERMA_LOGO_BLACK_RGB.jpg\",\"articleSection\":[\"Industry\"],\"inLanguage\":\"en-US\"},{\"@type\":\"WebPage\",\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/galderma-completes-successful-placement-of-chf-175-million-bond\\\/\",\"url\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/galderma-completes-successful-placement-of-chf-175-million-bond\\\/\",\"name\":\"Galderma Completes Successful Placement of CHF 175 Million Bond - Pharma Trend\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/#website\"},\"primaryImageOfPage\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/galderma-completes-successful-placement-of-chf-175-million-bond\\\/#primaryimage\"},\"image\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/galderma-completes-successful-placement-of-chf-175-million-bond\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/mms.businesswire.com\\\/media\\\/20251113705213\\\/en\\\/2643381\\\/22\\\/GALDERMA_LOGO_BLACK_RGB.jpg\",\"datePublished\":\"2025-11-14T06:03:42+00:00\",\"breadcrumb\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/galderma-completes-successful-placement-of-chf-175-million-bond\\\/#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\\\/\\\/pharma-trend.com\\\/en\\\/galderma-completes-successful-placement-of-chf-175-million-bond\\\/\"]}]},{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/galderma-completes-successful-placement-of-chf-175-million-bond\\\/#primaryimage\",\"url\":\"https:\\\/\\\/mms.businesswire.com\\\/media\\\/20251113705213\\\/en\\\/2643381\\\/22\\\/GALDERMA_LOGO_BLACK_RGB.jpg\",\"contentUrl\":\"https:\\\/\\\/mms.businesswire.com\\\/media\\\/20251113705213\\\/en\\\/2643381\\\/22\\\/GALDERMA_LOGO_BLACK_RGB.jpg\"},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/galderma-completes-successful-placement-of-chf-175-million-bond\\\/#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Startseite\",\"item\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"Galderma Completes Successful Placement of CHF 175 Million Bond\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/#website\",\"url\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/\",\"name\":\"Pharma Trend\",\"description\":\"\",\"publisher\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/#organization\"},\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"en-US\"},{\"@type\":\"Organization\",\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/#organization\",\"name\":\"Pharma Trend\",\"url\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/\",\"logo\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/#\\\/schema\\\/logo\\\/image\\\/\",\"url\":\"\",\"contentUrl\":\"\",\"caption\":\"Pharma Trend\"},\"image\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/#\\\/schema\\\/logo\\\/image\\\/\"}},{\"@type\":\"Person\",\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/#\\\/schema\\\/person\\\/02d41342c7a74fa7f0032bb35ef0bb24\",\"name\":\"Business Wire\"}]}<\/script>\n<!-- \/ Yoast SEO plugin. -->","yoast_head_json":{"title":"Galderma Completes Successful Placement of CHF 175 Million Bond - Pharma Trend","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/pharma-trend.com\/en\/galderma-completes-successful-placement-of-chf-175-million-bond\/","og_locale":"en_US","og_type":"article","og_title":"Galderma Completes Successful Placement of CHF 175 Million Bond - Pharma Trend","og_description":"ZUG, Switzerland–(BUSINESS WIRE)–NOT FOR DISTRIBUTION IN THE UNITED STATES OR IN ANY OTHER JURISDICTION IN WHICH SUCH DISTRIBUTION WOULD BE RESTRICTED BY APPLICABLE LAW OR REGULATION. Galderma Group AG (SIX:GALD), the pure-play dermatology category leader, today announced the successful placement of a single-tranche CHF 175 million Swiss franc-denominated bond. The bond has a maturity of ... [Read more...]","og_url":"https:\/\/pharma-trend.com\/en\/galderma-completes-successful-placement-of-chf-175-million-bond\/","og_site_name":"Pharma Trend","article_published_time":"2025-11-14T06:03:42+00:00","og_image":[{"url":"https:\/\/mms.businesswire.com\/media\/20251113705213\/en\/2643381\/22\/GALDERMA_LOGO_BLACK_RGB.jpg","type":"","width":"","height":""}],"author":"Business Wire","twitter_card":"summary_large_image","twitter_misc":{"Written by":"Business Wire","Est. reading time":"4 minutes"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/pharma-trend.com\/en\/galderma-completes-successful-placement-of-chf-175-million-bond\/#article","isPartOf":{"@id":"https:\/\/pharma-trend.com\/en\/galderma-completes-successful-placement-of-chf-175-million-bond\/"},"author":{"name":"Business Wire","@id":"https:\/\/pharma-trend.com\/en\/#\/schema\/person\/02d41342c7a74fa7f0032bb35ef0bb24"},"headline":"Galderma Completes Successful Placement of CHF 175 Million Bond","datePublished":"2025-11-14T06:03:42+00:00","mainEntityOfPage":{"@id":"https:\/\/pharma-trend.com\/en\/galderma-completes-successful-placement-of-chf-175-million-bond\/"},"wordCount":724,"publisher":{"@id":"https:\/\/pharma-trend.com\/en\/#organization"},"image":{"@id":"https:\/\/pharma-trend.com\/en\/galderma-completes-successful-placement-of-chf-175-million-bond\/#primaryimage"},"thumbnailUrl":"https:\/\/mms.businesswire.com\/media\/20251113705213\/en\/2643381\/22\/GALDERMA_LOGO_BLACK_RGB.jpg","articleSection":["Industry"],"inLanguage":"en-US"},{"@type":"WebPage","@id":"https:\/\/pharma-trend.com\/en\/galderma-completes-successful-placement-of-chf-175-million-bond\/","url":"https:\/\/pharma-trend.com\/en\/galderma-completes-successful-placement-of-chf-175-million-bond\/","name":"Galderma Completes Successful Placement of CHF 175 Million Bond - Pharma Trend","isPartOf":{"@id":"https:\/\/pharma-trend.com\/en\/#website"},"primaryImageOfPage":{"@id":"https:\/\/pharma-trend.com\/en\/galderma-completes-successful-placement-of-chf-175-million-bond\/#primaryimage"},"image":{"@id":"https:\/\/pharma-trend.com\/en\/galderma-completes-successful-placement-of-chf-175-million-bond\/#primaryimage"},"thumbnailUrl":"https:\/\/mms.businesswire.com\/media\/20251113705213\/en\/2643381\/22\/GALDERMA_LOGO_BLACK_RGB.jpg","datePublished":"2025-11-14T06:03:42+00:00","breadcrumb":{"@id":"https:\/\/pharma-trend.com\/en\/galderma-completes-successful-placement-of-chf-175-million-bond\/#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/pharma-trend.com\/en\/galderma-completes-successful-placement-of-chf-175-million-bond\/"]}]},{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/pharma-trend.com\/en\/galderma-completes-successful-placement-of-chf-175-million-bond\/#primaryimage","url":"https:\/\/mms.businesswire.com\/media\/20251113705213\/en\/2643381\/22\/GALDERMA_LOGO_BLACK_RGB.jpg","contentUrl":"https:\/\/mms.businesswire.com\/media\/20251113705213\/en\/2643381\/22\/GALDERMA_LOGO_BLACK_RGB.jpg"},{"@type":"BreadcrumbList","@id":"https:\/\/pharma-trend.com\/en\/galderma-completes-successful-placement-of-chf-175-million-bond\/#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Startseite","item":"https:\/\/pharma-trend.com\/en\/"},{"@type":"ListItem","position":2,"name":"Galderma Completes Successful Placement of CHF 175 Million Bond"}]},{"@type":"WebSite","@id":"https:\/\/pharma-trend.com\/en\/#website","url":"https:\/\/pharma-trend.com\/en\/","name":"Pharma Trend","description":"","publisher":{"@id":"https:\/\/pharma-trend.com\/en\/#organization"},"potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/pharma-trend.com\/en\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"},{"@type":"Organization","@id":"https:\/\/pharma-trend.com\/en\/#organization","name":"Pharma Trend","url":"https:\/\/pharma-trend.com\/en\/","logo":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/pharma-trend.com\/en\/#\/schema\/logo\/image\/","url":"","contentUrl":"","caption":"Pharma Trend"},"image":{"@id":"https:\/\/pharma-trend.com\/en\/#\/schema\/logo\/image\/"}},{"@type":"Person","@id":"https:\/\/pharma-trend.com\/en\/#\/schema\/person\/02d41342c7a74fa7f0032bb35ef0bb24","name":"Business Wire"}]}},"_links":{"self":[{"href":"https:\/\/pharma-trend.com\/en\/wp-json\/wp\/v2\/posts\/62204","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/pharma-trend.com\/en\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/pharma-trend.com\/en\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/pharma-trend.com\/en\/wp-json\/wp\/v2\/users\/4"}],"replies":[{"embeddable":true,"href":"https:\/\/pharma-trend.com\/en\/wp-json\/wp\/v2\/comments?post=62204"}],"version-history":[{"count":0,"href":"https:\/\/pharma-trend.com\/en\/wp-json\/wp\/v2\/posts\/62204\/revisions"}],"wp:attachment":[{"href":"https:\/\/pharma-trend.com\/en\/wp-json\/wp\/v2\/media?parent=62204"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/pharma-trend.com\/en\/wp-json\/wp\/v2\/categories?post=62204"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/pharma-trend.com\/en\/wp-json\/wp\/v2\/tags?post=62204"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}